Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using antisense drug discovery platform. Its product pipeline comprises 26 drugs to primarily treat cardiovascular, metabolic, severe, and rare diseases, as well as cancer. The company’s flagship product, KYNAMRO, is an apo-B synthesis inhibitor in development for the reduction of low-density lipoprotein cholesterol. The company has collaboration agreements with Biogen Idec to develop and commercialize ISIS-SMNRx for the treatment of spinal muscular atrophy; Bristol-Myers Squibb to discover, develop, and commercialize antisense drugs targeting proprotein convertase subtilisin/kexin type 9; and Ortho-McNeil-Janssen Pharmaceuticals, Inc. to discover, develop, and commercialize antisense drugs to treat metabolic diseases, including type 2 diabetes. It also has a strategic relationship with Eli Lilly and Company for the development of LY2181308, an antisense inhibitor of survivin; and a strategic alliance with GlaxoSmithKline to develop new drugs against targets for rare and serious diseases. The company was founded in 1989 and is headquartered in Carlsbad, California.